User login
Key clinical point: Atezolizumab plus nab-paclitaxel shows no overall survival (OS) advantage in patients with advanced/metastatic triple-negative breast cancer (TNBC) overall, but improves OS in in a patient subgroup positive for programmed death-ligand 1 (PD-L1) expression in tumor-infiltrating immune cells.
Major finding: There was no difference in OS in the intent-to-treat population (P = .077). An exploratory analysis in the PD-L1 immune cell-positive population showed OS improvement with atezolizumab plus nab-paclitaxel (stratified hazard ratio, 0.67; 95% confidence interval, 0.53-0.86).
Study details: A randomized, double-blind, placebo-controlled phase 3 IMpassion130 trial of 902 patients with advanced/metastatic TNBC who received atezolizumab plus nab-paclitaxel (n=451) or placebo plus nab-paclitaxel (n=451).
Disclosures: This study was sponsored by F. Hoffmann-La Roche Ltd./Genentech, Inc. The authors received honoraria, travel support, research funding, consulting/advisory/steering committee fees, and grants from various sources. Some of the authors were employed by and/or owned stocks in Genentech/Roche.
Source: Emens LA et al. Ann Oncol. 2021 Jul 1. doi: 10.1016/j.annonc.2021.05.355.
Key clinical point: Atezolizumab plus nab-paclitaxel shows no overall survival (OS) advantage in patients with advanced/metastatic triple-negative breast cancer (TNBC) overall, but improves OS in in a patient subgroup positive for programmed death-ligand 1 (PD-L1) expression in tumor-infiltrating immune cells.
Major finding: There was no difference in OS in the intent-to-treat population (P = .077). An exploratory analysis in the PD-L1 immune cell-positive population showed OS improvement with atezolizumab plus nab-paclitaxel (stratified hazard ratio, 0.67; 95% confidence interval, 0.53-0.86).
Study details: A randomized, double-blind, placebo-controlled phase 3 IMpassion130 trial of 902 patients with advanced/metastatic TNBC who received atezolizumab plus nab-paclitaxel (n=451) or placebo plus nab-paclitaxel (n=451).
Disclosures: This study was sponsored by F. Hoffmann-La Roche Ltd./Genentech, Inc. The authors received honoraria, travel support, research funding, consulting/advisory/steering committee fees, and grants from various sources. Some of the authors were employed by and/or owned stocks in Genentech/Roche.
Source: Emens LA et al. Ann Oncol. 2021 Jul 1. doi: 10.1016/j.annonc.2021.05.355.
Key clinical point: Atezolizumab plus nab-paclitaxel shows no overall survival (OS) advantage in patients with advanced/metastatic triple-negative breast cancer (TNBC) overall, but improves OS in in a patient subgroup positive for programmed death-ligand 1 (PD-L1) expression in tumor-infiltrating immune cells.
Major finding: There was no difference in OS in the intent-to-treat population (P = .077). An exploratory analysis in the PD-L1 immune cell-positive population showed OS improvement with atezolizumab plus nab-paclitaxel (stratified hazard ratio, 0.67; 95% confidence interval, 0.53-0.86).
Study details: A randomized, double-blind, placebo-controlled phase 3 IMpassion130 trial of 902 patients with advanced/metastatic TNBC who received atezolizumab plus nab-paclitaxel (n=451) or placebo plus nab-paclitaxel (n=451).
Disclosures: This study was sponsored by F. Hoffmann-La Roche Ltd./Genentech, Inc. The authors received honoraria, travel support, research funding, consulting/advisory/steering committee fees, and grants from various sources. Some of the authors were employed by and/or owned stocks in Genentech/Roche.
Source: Emens LA et al. Ann Oncol. 2021 Jul 1. doi: 10.1016/j.annonc.2021.05.355.